for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alnylam Pharmaceuticals, Inc.

ALNY.O

Latest Trade

78.97USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

60.27

 - 

96.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
78.97
Open
--
Volume
--
3M AVG Volume
15.28
Today's High
--
Today's Low
--
52 Week High
96.08
52 Week Low
60.27
Shares Out (MIL)
111.21
Market Cap (MIL)
8,782.07
Forward P/E
-9.84
Dividend (Yield %)
--

Next Event

Q3 2019 Alnylam Pharmaceuticals Inc Earnings Release

Latest Developments

More

Alnylam Announces Filing For Marketing Authorization Of Onpattro In Brazil For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Says U.S. FDA Granted Priority Review For Acute Hepatic Porphyria Treatment Givosiran

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry

Biotechnology & Drugs

Contact Info

300 3rd St

+1.617.5518200

http://www.alnylam.com/

Executive Leadership

Michael W. Bonney

Independent Chairman of the Board

Barry E. Greene

President

John M. Maraganore

Chief Executive Officer, Director

Jeffrey V Poulton

Chief Financial Officer, Executive Vice President

Akshay K. Vaishnaw

President - Research and Development

Key Stats

2.06 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.2K
EPS (USD)

2016

-4.790

2017

-5.420

2018

-7.570

2019(E)

-8.029
Price To Earnings (TTM)
--
Price To Sales (TTM)
86.86
Price To Book (MRQ)
4.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.71
LT Debt To Equity (MRQ)
1.71
Return on Investment (TTM)
-42.24
Return on Equity (TTM)
-38.09

Latest News

Latest News

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Alnylam, Regeneron to partner for RNAi treatments

Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Side effects of Alnylam's gene-silencing drug raise concerns, shares slip

Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease.

Alnylam's gene-silencing drug meets main goal in late-stage study

Alnylam Pharmaceuticals Inc said on Wednesday its gene-silencing drug for treating a rare, painful disease met the main goal in a late-stage trial.

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

BRIEF-Alnylam Pharmaceuticals Says On May 12, Co's Board Expanded Size Of Board From Ten To Eleven

* ALNYLAM PHARMACEUTICALS INC SAYS ON MAY 12, CO'S BOARD EXPANDED SIZE OF BOARD FROM TEN TO ELEVEN - SEC FILING Source http://bit.ly/2KrXrlM Further company coverage:

BRIEF-Alnylam Appoints Colleen Reitan To The Board Of Directors

* ALNYLAM APPOINTS COLLEEN REITAN TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics

* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran

* ALNYLAM ACHIEVES ALIGNMENT WITH FDA ON ACCELERATED DEVELOPMENT PATH FOR LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis

* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

BRIEF-Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent

* CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT

BRIEF-Silence Therapeutics Brings Patent Infringement Proceedings Against Alnylam's Patisiran Product

* SAYS BROUGHT PATENT INFRINGEMENT PROCEEDINGS IN PORTUGAL AGAINST ALNYLAM'S PATISIRAN PRODUCT Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up